July 6, 2010 – C. R. Bard Inc. announced today that it has completed its acquisition of SenoRx Inc., a manufacturer of breast cancer treatment devices. Under the terms of the merger agreement, SenoRx stockholders will receive $11 in cash for each share held of SenoRx common stock, a premium of approximately 14 percent over the closing price of SenoRx shares on May 4, 2010, the last trading day before the public announcement of the acquisition.
With the closing of the transaction, trading in SenoRx common shares was suspended. SenoRx common shares ceased to trade on NASDAQ at market close July 6 and were delisted.
SenoRx develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor vacuum-assisted breast biopsy system and Contura MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx’s field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S.
April 10, 2026 
